Role of Nitric Oxide–cGMP Pathway in Adrenomedullin-Induced Vasodilation in the Rat


Abstract—We previously reported that adrenomedullin (AM), a potent vasodilator peptide discovered in pheochromocytoma cells, stimulates nitric oxide (NO) release in the rat kidney. To further investigate whether the NO-cGMP pathway is involved in the mechanisms of AM-induced vasodilation, we examined the effects of E-4021, a cGMP-specific phosphodiesterase inhibitor, on AM-induced vasorelaxation in aortic rings and perfused kidneys isolated from Wistar rats. We also measured NO release from the kidneys using a chemiluminescence assay. AM (10^{-10} to 10^{-7} mol/L) relaxed the aorta precontracted with phenylephrine in a dose-dependent manner. Denudation of endothelium (E) attenuated the vasodilatory action of AM (10^{-7} mol/L: AM: intact (E+) −25.7±5.2% versus denuded (E−) −7.8±0.6%, P<0.05). On the other hand, pretreatment with 10^{-8} mol/L E-4021 augmented AM-induced vasorelaxation in the intact aorta (−49.0±7.9%, P<0.05) but not in the denuded one. E-4021 also increased acetylcholine (ACh)-induced vasorelaxation in the rat intact aorta (10^{-7} mol/L ACh −36.6±8.4% versus 10^{-8} mol/L E-4021+10^{-7} mol/L ACh −62.7±3.1%, P<0.05). In perfused kidneys, AM-induced vasorelaxation was also augmented by preincubation with E-4021 (10^{-9} mol/L AM −15.4±0.6% versus 10^{-8} mol/L E-4021+10^{-9} mol/L AM −23.6±1.2%, P<0.01). AM significantly increased NO release from rat kidneys (ANO: +11.3±0.8 fmol min^{-1} g^{-1} kidney at 10^{-9} mol/L AM), which was not affected by E-4021. E-4021 enhanced ACh-induced vasorelaxation (10^{-9} mol/L ACh −9.7±1.7% versus 10^{-8} mol/L E-4021+10^{-9} mol/L ACh −18.8±2.9%, P<0.01) but did not affect ACh-induced NO release from the kidneys. In the aorta and the kidney, 10^{-4} mol/L of N^δ-nitro-L-arginine methyl ester, an NO synthase inhibitor, and 10^{-7} mol/L of methylene blue, a guanylate cyclase inhibitor, reduced the vasodilatory effect of AM. These results suggest that the NO-cGMP pathway is involved in the mechanism of AM-induced vasorelaxation, at least in the rat aorta and kidney. (Hypertension. 1999;33:689-693.)

Key Words: adrenomedullin • nitric oxide • cyclic GMP • endothelium • phosphodiesterase inhibitors • rats

Adrenomedullin (AM) is originally isolated from the pheochromocytoma cells by assaysing the activity to increase platelet cAMP.1 AM increases intracellular cAMP in cultured vascular smooth muscle cells (VSMCs)2–3 and mesangial cells.4 It is well established that the increase in intracellular cAMP of VSMC is associated with endothelium-independent vasorelaxation. On the other hand, Shimakake et al5 observed that AM increased cGMP in rat aortic strips and that this effect was suppressed by pretreatment with N^\omega-monomethyl-L-arginine (L-NMMA), a nitric oxide synthase (NOS) inhibitor. This finding suggests that the nitric oxide (NO)–cGMP pathway may be involved at least in part in the mechanisms of AM-induced vasodilation. We have also reported that AM decreased renal vascular resistance in the rat isolated perfused kidney.6 This vasodilation was associated with a dose-dependent increase in NO release, which was measured with a chemiluminescence method.

Numerous studies other than the reports noted above have been conducted to explore the mechanisms for AM-induced vasodilation. However, it is still controversial whether it is endothelium-dependent6–8 or -independent.9,10 Most studies evaluated the endothelium-dependency of AM-induced vasodilation with NOS inhibitors such as L-NMMA. However, because the NOS inhibitors sometimes increase baseline vascular tone, it is difficult to get a clear-cut conclusion. Therefore, some other evidence in addition to NOS inhibition may be required to demonstrate the mechanisms of AM-induced vasodilation.

Because cGMP is degraded and inactivated by phosphodiesterase (PDE) in VSMCs, cGMP-specific PDE inhibitors may enhance the effects of NO. Actually, Thusu et al11 reported that zaprinast, a cGMP-specific type V PDE inhibitor, augmented the vasodilatory effect of a NO donor on...
isolated pulmonary arteries. Cohen et al 12 also demonstrated that cGMP-specific PDE inhibition reduced pulmonary artery resistance in conscious pulmonary hypertensive rats.

In the present study, to further explore whether the NO-cGMP pathway is involved in AM-induced vasodilation, we examined the effects of E-4021 [1-(6-chloro-4-(3,4-methylenylbenzyl) amino-quinazoline-2-yl) piperidine-4-carboxylate], a cGMP-specific type V PDE inhibitor 13 on AM-induced vasodilation in rat aortic rings and isolated perfused kidneys.

Methods

Organ Chamber Experiments

Vascular responses of the thoracic aorta from 12-week-old male Wistar rats were tested in organ chambers according to a technique previously described. 14 Briefly, the thoracic aorta was excised from the rat, and aortic rings (4 mm in length) were mounted in organ chambers filled with 25 mL of an oxygenated Krebs-Ringer bicarbonate solution at 37°C. Isometric tension was recorded with a force transducer (Oriental).

The aortic rings were precontracted with l-norepinephrine, and responses to AM (10^{-10} to 10^{-7} mol/L) at 70% of maximal contraction obtained in each individual ring (n = 6 each) were studied in the presence or absence of the vascular endothelium. The endothelium of the aortic ring was removed by gentle rubbing with a stainless steel needle. To evaluate the role of the NO-cGMP pathway, the responses to AM were tested in the presence of N^\gamma-nitro-\alpha-arginine methyl ester (L-NAME), a NOS inhibitor, methylene blue, a guanylate cyclase inhibitor, or E-4021. We also evaluated the effects of E-4021 on acetylcholine (ACh)-induced vasorelaxation (10^{-5} mol/L). RPP, which was maintained about 100 mm Hg by 6 mol/L phenylephrine, was significantly decreased, by as much as 30% at the dose of 10^{-7} mol/L.

Calculations and Statistical Analysis

Results of the experiments are given as the mean±SEM. Data were analyzed by ANOVA for repeated measures. Effects of agents were assessed by Dunnett’s test. Differences of P<0.05 were considered statistically significant.

Results

In the aortic rings, 10^{-10} to 10^{-7} mol/L of AM caused a dose-dependent vasorelaxation. This effect of AM was significantly attenuated by endothelium denudation (Figure 1a), which abolished the vasorelaxant effect of ACh. In the presence of 10^{-4} mol/L of L-NAME, AM-induced relaxation was also significantly attenuated (Figure 1b). Furthermore, 10^{-7} mol/L of methylene blue inhibited AM-induced vasorelaxation at 10^{-9} to 10^{-7} mol/L (Figure 1c). Methylene blue and L-NAME inhibited the effects of AM by 40% and 74%, respectively. On the other hand, 10^{-8} mol/L E-4021 significantly augmented the vasorelaxation induced by AM by 91% at 10^{-7} mol/L AM (Figure 2a). The effects of E-4021 on ACh-induced vascular relaxation, which is known as a cGMP-dependent response, were also tested in the aortic rings (Figure 2b). E-4021 significantly enhanced ACh-induced vasorelaxation by about 30% at the dose of 10^{-9} to 10^{-6} mol/L.

In the isolated perfused kidney, E-4021 per se caused a dose-dependent decrease in RPP between 10^{-8} and 10^{-6} mol/L. RPP, which was maintained about 100 mm Hg by 10^{-6} mol/L phenylephrine, was significantly decreased, by as much as 30% at the dose of 10^{-6} mol/L.
much as 30% during the infusion of $10^{-6}$ mol/L E-4021 (data not shown). Therefore, we used $10^{-8}$ mol/L E-4021 as pretreatment because this concentration of E-4021 caused only a 5% reduction in baseline RPP. As shown in Figure 3, ACh caused potent vasodilation and NO release in a dose-dependent manner. E-4021 potentiated these effects at either concentration. However, NO release was not influenced by E-4021. Although salbutamol showed a potent vasodilatory action, it did not cause release of NO at all. The PDE inhibitor altered neither salbutamol-induced vasodilation nor NO release (Figure 4). Figure 5 demonstrates the effects of E-4021 and L-NAME on the renal vasorelaxation induced by AM. AM decreased RPP in a dose-dependent manner between $10^{-11}$ and $10^{-8}$ mol/L. This renal vasorelaxation was associated with NO release, although the degree was smaller than that caused by ACh. AM-induced vasodilation was significantly augmented by pretreatment with E-4021. However, NO release induced by AM was not affected by E-4021. On the other hand, NOS inhibition by L-NAME decreased both renal vasodilation and NO release at any dose of AM.

**Discussion**

AM is a potent vasodilator peptide particularly in the renal vessels. As mentioned before, cAMP has been considered to be a primary second messenger of AM. In fact, Ishizaka et al and Eguchi et al reported that AM increased cAMP in cultured rat VSMCs in a dose-dependent manner. AM also increases cAMP in renal tubular cells, mesangial cells, and endothelial cells. In VSMCs, increases in cAMP result in activation of protein kinase A, increasing in turn Ca$^{2+}$ efflux through the Ca$^{2+}$ pump. Kureishi et al showed that AM decreased high K-induced contraction and [Ca$^{2+}$], in porcine coronary arteries.

However, we have suggested another possible mechanism for the vasodilatory action of AM. To examine the possible involvement of the NO-cGMP pathway in AM-induced vasorelaxation, we examined the effects of a cGMP-specific PDE inhibitor on vasorelaxation induced by AM in the aorta and renal vessels of rats. E-4021 has been reported to be a cGMP-specific type V PDE inhibitor. Cohen et al showed that PDE inhibition by E-4021 increased the cGMP.
In the present study, AM-induced vasorelaxation was augmented by E-4021. As shown in Figures 3 and 5, there were no differences in the vasodilator responses to the maximal dose of AM or ACh between control and E-4021-treated kidneys. In our system of the isolated perfused kidney precontracted with phenylephrine, the maximal responses to endothelium-dependent vasodilators are about 50% in terms of reductions of RPP. The responses to the maximal dose of AM or ACh used in this study almost reached this level. Therefore, in this condition, the addition of E-4021 might not augment the vasodilator responses to AM or ACh. This stimulatory effect of the PDE inhibitor on AM-induced renovascular relaxation was also observed in aortic rings. These observations suggest that a cGMP-mediated mechanism is involved in AM-induced vasorelaxation. Furthermore, vascular relaxation by AM was attenuated by denudation of the endothelium, a guanylate cyclase inhibitor, or a NOS inhibitor. It is well established that when guanylate cyclase is stimulated by NO, cGMP is increased in VSMCs. These findings show that AM-induced vasorelaxation is, at least in part, NO-mediated in the thoracic aortas and renal arteries of rats.

However, the controversy as to whether AM-induced relaxation is endothelium-dependent or not still persists. Miura et al. reported that renal vasodilation caused by intra-arterial administration of AM in dogs was suppressed by N\textsuperscript{G}-nitro-L-arginine and that an excessive amount of L-arginine restored this suppression. On the other hand, Gardiner et al. reported that AM-induced vasodilation in the hindquarter was only slightly inhibited by L-NAME. Heaton et al. also observed that L-NAME did not antagonize the vasodilatory effect of AM in pulmonary vessels of the rat. It is possible that the endothelium-dependency of the action of AM depends on differences in vascular beds.

The mechanism of NO release by AM is not clear in this study. However, because the vasodilatory response to AM occurred rapidly (less than 15 seconds), the type of NOS involved in AM-induced relaxation may be constitutive NOS. In addition, we previously showed an increase in [Ca\textsuperscript{2+}], transient of cultured bovine carotid endothelial cells in response to AM. The activity of endothelial constitutive NOS depends on intracellular Ca\textsuperscript{2+} and calmodulin concentration. Shimekake et al. also demonstrated that AM increased intracellular Ca\textsuperscript{2+} and cGMP in cultured bovine aortic endothelial cells. It is possible that the increase in [Ca\textsuperscript{2+}], induced by AM activates endothelial constitutive NOS and increases NO release from the vascular endothelium. On the other hand, it has been reported that there is a site for phosphorylation by cAMP-dependent protein kinase on endothelial NOS. Although the structures of the putative receptors for AM and calcitonin gene-related peptide have been demonstrated, their intracellular signaling or distribution has not been clarified. Some receptors such as calcitonin receptors activate adenylate cyclase and phospholipase C. If AM receptors with such characteristics abundantly exist on the vascular endothelial cells, AM may increase [Ca\textsuperscript{2+}], and thereby NO release. In addition to the direct effect of NO on VSMCs, it is possible that endothelium-derived NO potentiates other receptors or channels to promote further relaxation in response to AM. Bolotina et al demonstrated that NO directly activates Ca-dependent K channels in VSMCs. Furthermore, NO reduces the production of vasoconstrictive substances (eg, endothelin) through a cGMP-dependent mechanism.

In conclusion, the vasodilatory effect of AM is at least in part endothelium-dependent. Not only the cAMP-related mechanism but also the NO-cGMP pathway may be involved in AM-induced vasorelaxation in the rat aorta and kidney. Because vascular endothelial cells and smooth muscle cells synthesize AM, AM may contribute to the regulation of vascular tone through NO-cGMP signaling mechanisms.

**Acknowledgments**

This study was supported in part by Grants-in-Aid 07557055 and 09281206 from the Japanese Ministry of Education, Culture and Science, Japan. The authors thank Eisai Co (Tokyo, Japan) for generously providing E-4021 for this study.

**References**


Role of Nitric Oxide–cGMP Pathway in Adrenomedullin-Induced Vasodilation in the Rat
Hiroshi Hayakawa, Yasunobu Hirata, Masao Kakoki, Yasuko Suzuki, Hiroaki Nishimatsu, Daisuke Nagata, Etsu Suzuki, Kazuya Kikuchi, Tetsuo Nagano, Kenji Kangawa, Hisayuki Matsuo, Tsuneaki Sugimoto and Masao Omata

Hypertension. 1999;33:689-693
doi: 10.1161/01.HYP.33.2.689

Hypertension is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 1999 American Heart Association, Inc. All rights reserved.
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://hyper.ahajournals.org/content/33/2/689

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Hypertension can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Hypertension is online at:
http://hyper.ahajournals.org//subscriptions/